Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH)
will be reporting earnings this Wednesday before market hours. Here’s what investors should know.
Lantheus missed analysts’ revenue expectations by 1.6% last quarter, reporting revenues of $372.8 million, flat year on year. It was a disappointing quarter for the company, with a significant miss of analysts’ full-year EPS guidance estimates.
This quarter, analysts are expecting Lantheus’s revenue to decline 1.6% year on year to $387.8 million, a reversal from the 22.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.68 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Lantheus has missed Wall Street’s revenue estimates twice over the last two years.
Looking at Lantheus’s peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. GE HealthCare delivered year-on-year revenue growth of 3.5%, beating analysts’ expectations by 1%, and Hologic reported revenues up 1.2%, topping estimates by 1.7%. GE HealthCare traded down 8.3% following the results while Hologic was up 2.9%.
The euphoria surrounding Trump’s November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.3% on average over the last month. Lantheus is down 7.3% during the same time and is heading into earnings with an average analyst price target of $124.29 (compared to the current share price of $73.40).
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.